BIM
NTLA icon

BlackRock Investment Management’s Intellia Therapeutics NTLA Stock Holding History

BlackRock Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$339K Hold
25,834
– – ﹤0.01% 3139
2016
Q3 		$440K Sell
25,834
-66
-0.3% -$1.28K ﹤0.01% 3089
2016
Q2 		$553K Buy
+25,900
New +$689K ﹤0.01% 3010

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock Investment Management's NTLA Position: Q4 2016 in Review

BlackRock Investment Management held its Intellia Therapeutics (NTLA) position steady in Q4 2016 at 25,834 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #3139.

BlackRock Investment Management first reported a position in NTLA in Q2 2016 and has held it in 3 quarters since. The position peaked at $553K in Q2 2016. 70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • BlackRock Investment Management held 25,834 shares of Intellia Therapeutics worth $339K as of Q4 2016.
  • BlackRock Investment Management left its Intellia Therapeutics share count unchanged in Q4 2016.
  • Intellia Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3139 holding.
  • BlackRock Investment Management first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Investment Management's Intellia Therapeutics position peaked at $553K in Q2 2016.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.